SOUTH SAN FRANCISCO, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM - News) today announced the establishment of its European organization to facilitate access to Trofile, its proprietary tropism test, following the announcement that Pfizer Inc. (NYSE: PFE - News) has received European Commission approval of the novel HIV therapy, Celsentri® (maraviroc) tablets (known as Selzentry(TM) in the U.S.). Trofile was the assay used for patient selection for maraviroc’s clinical development program and the two companies are engaged in a collaboration agreement to make Monogram’s assay available for patient use globally.
